Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 605
Rating:

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Dr Harold Burstein comments on data, during a press conference at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, from the MONALEESA-7 trial.

This was a phase III randomised trial in which pre-menopausal women with advanced breast cancer received ribociclib on top of the standard of care endocrine therapy.

Watch Dr Hurvitz's press conference here, and interview here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation